MAINtenance Afinitor (MAIN-A): A randomized trial comparing maintenance aromatase inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients withHR+ metastatic breast cancer with disease control after first line chemotherapy
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Sep 2018
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Anastrozole; Exemestane; Letrozole
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms MAIN-A
- 18 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 Jun 2020.
- 18 Jul 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2019.
- 18 Jul 2018 Status changed from recruiting to active, no longer recruiting.